Wesley Bennett, MD
Interventional Cardiology · Meridian, MSNPI 1730166307
Payments from drug & device makers
Across 237 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abiomed$1K
- Novartis$1K
- Pfizer$225
- Celonova Biosciences, Inc.$217
- Philips North America LLC$207
- plus $1K from 26 others
What the payments were for
- Travel & lodging$1,01116%
- Food & beverage$5,36484%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 36 | $1,975 |
| Abiomed | 45 | $1,245 |
| Novartis | 80 | $1,135 |
| Pfizer | 15 | $225 |
| Celonova Biosciences, Inc. | 1 | $217 |
| Philips North America LLC | 3 | $207 |
| Merck | 10 | $184 |
| Amgen | 2 | $139 |
| AstraZeneca | 6 | $132 |
| Boston Scientific | 1 | $125 |
| Johnson & Johnson | 6 | $115 |
| E.r. Squibb & Sons, L.L.C. | 6 | $106 |
| Boehringer Ingelheim | 1 | $84 |
| Abbott | 5 | $79 |
| Shockwave Medical, Inc | 2 | $74 |
| Atricure, Inc. | 1 | $36 |
| W. L. Gore & Associates, Inc. | 1 | $31 |
| Silk Road Medical, Inc. | 1 | $28 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Bard Peripheral Vascular, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Terumo Medical Corporation | 1 | $20 |
| Cvrx, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Itamar Medical Inc | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Novo Nordisk | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADVISA DR MRI SURESCAN$590
- Micra$505
- Varithena Administration Pack$125
- VenaSeal$125
- Repatha$124
How this compares
$6,389 in reported general payments places this provider in the 30th percentile of 65 interventional cardiology providers in Mississippi.
See all interventional cardiology providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 664 | $618,571 |
| XareltoRivaroxaban | 190 | $215,879 |
| EntrestoSacubitril/Valsartan | 82 | $87,588 |
| Repatha SureclickEvolocumab | 58 | $48,999 |
| FarxigaDapagliflozin Propanediol | 54 | $47,108 |
| BrilintaTicagrelor | 62 | $41,234 |
| JardianceEmpagliflozin | 16 | $16,842 |
| MultaqDronedarone Hcl | 13 | $12,077 |
| OzempicSemaglutide | 11 | $11,068 |
| Metoprolol Succinate | 815 | $10,921 |
| Potassium Chloride | 321 | $8,342 |
| Rosuvastatin Calcium | 454 | $6,383 |
| Atorvastatin Calcium | 599 | $5,117 |
| Ranolazine ErRanolazine | 59 | $5,067 |
| Valsartan | 216 | $4,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $225 | $618,571664 claims |
| Johnson & JohnsonXarelto | $115 | $215,879190 claims |
| AstraZenecaFarxiga, Brilinta | $132 | $88,342116 claims |
| NovartisEntresto | $1,135 | $87,58882 claims |
| Boehringer IngelheimJardiance | $84 | $16,84216 claims |
| Sanofi-aventis U.S. LLCMultaq | $11 | $12,07713 claims |
| Novo NordiskOzempic | $12 | $11,06811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 65 interventional cardiology providers in Mississippi.
Other interventional cardiology in Meridian
- Wilson HannahMeridian$4K
- Brett BennettJackson$561K
- John WinscottJackson$482K
- William CrowderJackson$419K
- Foluso FakoredeCleveland$298K
- James BennettJackson$286K
- Steven KindsvaterKeesler Afb$197K
- Abdul BahroFlowood$132K
- Amit MalhotraSouthaven$131K
- Robert WilkinsHattiesburg$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.